Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kimberly Roddy

Nurse Practitioner, Family Jonesboro, AR Nurse Practitioner

NPI 1467908970 CMS profile 10944283

300 Carson St, Jonesboro, AR 72401

Open in the dashboard

General payments

$12,176

696 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kimberly Roddy of Jonesboro, AR is reported in the CMS Open Payments database as having received $12,176 across 696 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,085 161
2024 General $2,568 137
2023 General $2,951 155
2022 General $2,080 137
2021 General $1,493 106

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kimberly Roddy
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Kimberly Roddy were reported at $3,085. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Kimberly Roddy Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $1,493 $124 $35–$379 $132
2022 $2,080 $141 $44–$430 $149
2023 $2,951 $154 $49–$476 $160
2024 $2,568 $165 $51–$504 $164
2025 $3,085 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. GlaxoSmithKline, LLC. $2,125 122 payments
  2. AstraZeneca Pharmaceuticals LP $1,696 95 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $851 60 payments
  4. Regeneron Healthcare Solutions, Inc. $706 29 payments
  5. Genzyme Corporation $623 23 payments
  6. Jazz Pharmaceuticals Inc. $591 27 payments
  7. Genentech USA, Inc. $446 28 payments
  8. Amgen Inc. $398 26 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $344 19 payments
  10. AbbVie, Inc. $308 21 payments
  11. Other $4,087 246 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $12,090 694 payments
  2. Education $87 2 payments
Products named General payments · program years 2021–2025
  1. TRELEGY ELLIPTA $1,317 90 payments
  2. NUCALA $702 39 payments
  3. DUPIXENT Immunology $623 23 payments
  4. XYWAV $591 27 payments
  5. BREZTRI $551 23 payments
  6. DUPIXENT Inflammation And Immunology $514 19 payments
  7. Xolair $446 28 payments
  8. FASENRA $430 26 payments
  9. FARXIGA $414 19 payments
  10. AIRSUPRA $386 19 payments
  11. Other $8,006 503 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

1,376

Median for Nurse Practitioner: 389

Drug cost

$343,284

Median for Nurse Practitioner: $21,885

Branded share of claims

69.6%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 215 $138,986
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 122 $85,751
Breo Ellipta Fluticasone/Vilanterol Brand 46 $19,083
Symbicort Budesonide/Formoterol Fumarate Brand 63 $16,882
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 29 $15,271
Bevespi Aerosphere Glycopyrrolate/Formoterol Fum Brand 25 $11,273
Albuterol Sulfate Hfa Albuterol Sulfate Brand 252 $8,746
Combivent Respimat Ipratropium/Albuterol Sulfate Brand 16 $7,593
Spiriva Respimat Tiotropium Bromide Brand 14 $7,137
Advair Hfa Fluticasone Propion/Salmeterol Brand 14 $6,017

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$35,402

Medicare's payments for the services billed

Medicare patients

591

Average age 71

Services billed

884

317 women, 274 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
COPD 48%
Ischemic heart disease 44%
Diabetes 39%
Depression 38%
Atrial fibrillation 30%
Heart failure 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $256
  • GENZYME CORPORATION $136
$393 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $286
$286 215 —
OFEV
  • Boehringer Ingelheim Pharmaceuticals, Inc. $207
$207 — —
AREXVY
  • GlaxoSmithKline, LLC. $182
$182 — —
XYWAV
  • JAZZ PHARMACEUTICALS INC. $182
$182 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

696 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record